David Gill

Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.

EndoChoice, Inc. operates as a medtech company which focuses on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices, and infection control products and pathology services. Its imaging systems include fuse endoscopy system, fuse accesories, carts, cart options, monitors, monitor cart mounts, monito wall mounts, scope services, and suction pumps and supplies. Its devices include band ligators, biopsy forceps, bipolar probes, bite blocks, cytology brushes, electrosurgical supplies, metal stents, needles, retrieval devices, and snares. The company was founded by Mark G. Gilreath and William Parks in 2007 and is headquartered in Alpharetta, GA.

TransEnterix is advancing the field of minimally invasive surgery through exploration, innovation and collaboration. Based in North Carolina's Research Triangle Park, TransEnterix is a rapidly growing medical device company founded in 2006. Since its inception the company has designed, received FDA approval and launched the groundbreaking SPIDER Surgical System, which provides surgeons with enhanced capabilities by creating triangulation via single site access with flexible articulating instruments. The platform enables a whole new class of less invasive surgery - Flexible Laparoscopy - which builds on the proven technologies of laparoscopic surgery and catheter based medical treatments.

Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its products include; Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC.

Novum Medical, Inc. operates as a medical device company. It engages in the development of advanced orthobiomaterials utilizing a proprietary process capable of producing structures that are both strong and porous. The company was founded by Paul K. Nichols, Jr. and is headquartered in Woburn, MA.

EndoChoice Holdings, Inc. engages in the development, design and manufacture of medical devices. It offers span single-use devices and infection control products, pathology and imaging systems. The company was founded by Mark G. Gilreath and William Parks in 2008 and is headquartered in Alpharetta, GA.

Syneos Health LLC operates therapeutically focused global contract research organization. It provides pharma and biotech services. The firm specializes in the hematology, immunology and inflammation infectious diseases, oncology, ophthalmology, cardiovascular, CNS analgesia, CNS neurology, CNS psychiatry, endocrinology, and gastroenterology and hepatology. The company was founded by Kenneth A. Selzer in 1985 and is headquartered in Raleigh, NC.

NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the System One and PureFlow SL equipment and the sale of disposable products in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. The Services segment includes revenues from dialysis services provided to patients at its recently opened NxStage Kidney Care dialysis centers. The company was founded by Jeffrey H. Burbank in December 1998 and is headquartered in Waltham, MA.

EOS Imaging SA engages in the development and marketing of imaging and imaged-based solutions for diagnosing, treating, and monitoring common musculoskeletal pathologies. It operates through the France and North America geographical segments. The firm trademarks include EOSedge, sterEOS, spineEOS, hipEOS, and kneeEOS. The company was founded by Georges Charpak on February 8, 1989 and is headquartered in Paris, France.

Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark.

IsoTis Orthobiologics Inc. develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. Its products include bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. The company was founded in 2003 and is headquartered in Irvine, CA.

INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.

RapidPulse, Inc. is a medical device company that specializes in developing minimally invasive vascular products for ischemic stroke. The company is based in Miami, FL. The company is focused on advancing the development of the RapidPulse™ cyclic aspiration system, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC, a medical device incubator dedicated to developing innovative products in the medical device industry. The CEO of the company is Sean McBrayer.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.